<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02524444</url>
  </required_header>
  <id_info>
    <org_study_id>FDAAA</org_study_id>
    <nct_id>NCT02524444</nct_id>
  </id_info>
  <brief_title>A Comparative Study of Mefloquine and S-P as Prophylaxis Against Malaria in Pregnant HIV + Patients</brief_title>
  <official_title>A Comparative Study of Mefloquine and Sulphadoxine-pyrimethamine as Prophylaxis Against Malaria in Pregnant Human Immunodeficiency Virus Positive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ORIYOMI OMOTOYOSI AKINYOTU</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Ibadan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Ibadan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized controlled single blind prospective comparative study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is intended to be a randomized controlled single blind prospective comparative
      study conducted to compare the efficacy of three, monthly doses of sulphadoxine-pyrimethamine
      as intermittent preventive therapy with Mefloquine as-intermittent preventive therapy in
      HIV-infected pregnant women.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Level of malaria parasitemia in HIV positive women at delivery after administration of Mefloquine or sulphadoxine-pyrimethamine as prophylaxis for malaria in pregnancy</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">142</enrollment>
  <condition>Malaria in Pregnant HIV + Patients</condition>
  <arm_group>
    <arm_group_label>Mefloquine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tabs Mefloquine 250mg 3 doses 4 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sulphadoxine-Pyrimethamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets 4 weeks apart for 3 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mefloquine</intervention_name>
    <description>Tabs Mefloquine 250mg</description>
    <arm_group_label>Mefloquine</arm_group_label>
    <other_name>Larimef</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulphadoxine-Pyrimethamine</intervention_name>
    <description>Sulphadoxine 500mg , Pyrimethamine 25mg</description>
    <arm_group_label>Sulphadoxine-Pyrimethamine</arm_group_label>
    <other_name>Vitadar, Fansidar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant HIV positive patients

          -  Gestational age 16 weeks and above

          -  No history of use of Mefloquine or Sulphadoxine

          -  Pyrimethamine four weeks prior to recruitment.

        Exclusion Criteria:

          -  Anaemia packed cell volume less than 30%

          -  Pre -existing medical conditions- Diabetes Mellitus, -Hypertension

          -  Allergy to Sulphadoxine- Pyrimethamine or Mefloquine

          -  Non-consenting patients

          -  Multiple gestation

          -  Known psychiatric illness

          -  Known seizure disorder

          -  History of severe renal or hepatic disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AYODELE O AROWOJOLU, MBBS IBADAN</last_name>
    <role>Study Director</role>
    <affiliation>UNIVERSITY COLLEGE HOSPITAL,IBADAN,OYO STATE, NIGERIA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ORIYOMI O AKINYOTU, MBBS IBADAN</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNIVERSITY COLLEGE HOSPITAL,IBADAN,OYO STATE,NIGERIA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ADENIKE F BELLO, MBBS IBADAN</last_name>
    <role>Study Director</role>
    <affiliation>UNIVERSITY COLLEGE HOSPITAL,IBADAN,OYO STATE, NIGERIA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>Ibadan</city>
        <state>OYO State</state>
        <zip>200001</zip>
        <country>Nigeria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Nigeria</country>
  </location_countries>
  <reference>
    <citation>Steketee RW, Wirima JJ, Slutsker L, Khoromana CO, Heymann DL, Breman JG. Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. Am J Trop Med Hyg. 1996;55(1 Suppl):50-6.</citation>
    <PMID>8702037</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2015</study_first_submitted>
  <study_first_submitted_qc>August 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2015</study_first_posted>
  <last_update_submitted>December 7, 2017</last_update_submitted>
  <last_update_submitted_qc>December 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Ibadan</investigator_affiliation>
    <investigator_full_name>ORIYOMI OMOTOYOSI AKINYOTU</investigator_full_name>
    <investigator_title>SENIOR REGISTRAR</investigator_title>
  </responsible_party>
  <keyword>Intermittent preventive therapy</keyword>
  <keyword>malaria</keyword>
  <keyword>pregnant</keyword>
  <keyword>HIV positive</keyword>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>HIV Seropositivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyrimethamine</mesh_term>
    <mesh_term>Sulfadoxine</mesh_term>
    <mesh_term>Fanasil, pyrimethamine drug combination</mesh_term>
    <mesh_term>Mefloquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

